Patent application number | Description | Published |
20080269277 | Pyrrolopyridine-2-Carboxylic Acid Hydrazides - Compounds of Formula (I) or pharmaceutically acceptable salts thereof, are inhibitors of glycogen phosphorylase and are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia e.g. myocardial ischemia, or as cardioprotectants or inhibitors of abnormal cell growth. | 10-30-2008 |
20090023703 | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase - Compounds represented by Formula (I): | 01-22-2009 |
20090099227 | G-Protein Coupled Receptor Agonists - Compounds of Formula (I) or pharmaceutically acceptable salts or N-oxides thereof, are agonists of GPR116 and are useful for the treatment of obesity, and for the treatment of diabetes. | 04-16-2009 |
20090203676 | G-protein Coupled Receptor Agonists - Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes. | 08-13-2009 |
20090221644 | Gpcr Agonists - Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes. | 09-03-2009 |
20100035897 | Pyridine, pyrimidine and pyrazine derivatives as gpcr agonists - Compounds of formula (I): R | 02-11-2010 |
20100267780 | BICYCLIC ARYL AND HETEROARYL RECEPTOR MODULATORS - Compounds of formula (I) or pharmaceutically acceptable salts thereof, are opioid receptor modulators, e.g. mu-opioid receptor antagonists, neutral antagonists or inverse agonists, and are useful inter alia for the treatment of obesity. | 10-21-2010 |
20110086885 | Indole-2-carboxylic acid amides - Compounds represented by Formula (I) or pharmaceutically acceptable salts thereof, are useful in the prophylactic or therapeutic treatment of diabetes, hyperglycemia, hypercholesterolemia, hyperinsulinemia, hyperlipidemia, hypertension, atherosclerosis or tissue ischemia e.g. myocardial ischemia, and as cardioprotectants. | 04-14-2011 |
20120172358 | GPCR Agonists - Compounds of formula (I): | 07-05-2012 |